Replies to post #82391 on Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

To move to the NASDAQ and insure the funds will be able to purchase shares he'll want the share price in the range I've indicated.

Buy a few shares at the open on Tuesday this is headed much higher. The shorts and the market will soon figure out that there is substance here.

He's not moving to the NASDAQ with a share price in the $5.00 range. That is why it will be at a minimum of 1 for 10.

[hnbadger1]

#6 CANCER

Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure
Christopher C. Glembotski, The SDSU Heart Institute and the Department of Biology, San Diego State University, San Diego, CA 92182, USA


"Although there are many studies yet to be carried out, based on our current understanding of MANF structure and function, one would predict it to have therapeutic potential. Due to its potentially broad spectrum of action, a MANF-based therapeutic is predicted to be of high impact. All studies carried out to date that have examined the effects of MANF have demonstrated that it is protective in culture and in vivo. Moreover, this protection has been seen in multiple cell and tissue types, including the ischemic heart and brain, as well as in animal models of neurodegenerative disorders. Additionally, since MANF overexpression decreases proliferation of cultured cancer cells, and decreases cardiomyocyte hypertrophy, a MANF-based cancer therapy is conceivable. "

[zoomboom]

Armet/Manf and Creld2 are components of a specialized ER stress response provoked by inappropriate formation of disulphide bonds: implications for genetic skeletal diseases

ARMET also known as MANF which AMBS owns the Patents for.

Multiple Epiphyseal Dysplasia (MED). is another potential Orphan Indication

We demonstrate that Armet and Creld2 are genotype-specific ER stress response proteins with substrate specificities, and that aggregation of mutant matrilin-3 is a key disease trigger in MED that could be exploited as a potential therapeutic target.


http://hmg.oxfordjournals.org/content/early/2013/08/22/hmg.ddt383.abstract?sid=17d592a9-ef22-4702-9877-c535b6361d87